An observational study in Psoriasis (PsO), sponsored by Bristol-Myers Squibb. Recruiting at 1 site in United States. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Bristol-Myers Squibb · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Psoriasis by Bristol-Myers Squibb — 9 open to participants now, 14 under way, 4 of them phase 3. Psoriasis · Bristol-Myers Squibb.
Among the 42 studies in Psoriasis by Bristol-Myers Squibb, this one is the 4th largest by planned enrollment of the 14 observational ones that give a count, is one of 7 that started in 2025, is one of 14 observational ones, reaches primary completion later than 5 of the 13 other live ones, and was the 39th registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →9 of the 42 studies in Psoriasis by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Argentina, Belgium and 13 more countries
Ages 12–17
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 22 more countries
Ages 40+
Bristol-Myers Squibb · Sites in France, Switzerland
Ages 18+
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 19+
Bristol-Myers Squibb · Sites in Japan
Ages 18+
By country, each count listing its studies:
Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.
This study: female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 6 · Phase 3 9 · Phase 4 3
First in 1995; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 900 is above the median of 200 across 408 observational studies indexed under Psoriasis.
Median enrollment 131 across the 28 interventional studies, 528 across the 14 observational. Of the 28 that completed or were terminated, 10 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
3 of the studies in Psoriasis by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06710470Bristol-Myers SquibbA Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring | 2027-01-31 |
| NCT06512337Bristol-Myers SquibbA Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China | 2027-03-11 |
| NCT07256015Bristol-Myers SquibbDeucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy | 2027-07-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 42 studies in Psoriasis by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess pregnancy and infant outcomes among pregnant participants enrolled in an established North American pregnancy registry (Organization of Teratology Information Specialists [OTIS]) who were exposed to deucravacitinib.
The study population will include pregnant women participating in the The Organization of Teratology Information Specialists (OTIS) pregnancy registry in the US or Canada
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cohort 1: Deucravacitinib-exposed cohort
Cohort 2: PsO Disease-matched unexposed comparator cohort
Cohort 3: Non-disease unexposed comparator cohort
Exclusion Criteria
Cohort 1: Deucravacitinib-exposed cohort
Cohort 2: Disease-matched unexposed comparator cohort
Cohort 3: Non-disease unexposed comparator cohort
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pregnant participants with psoriasis exposed to deucravacitinib treatment
Drug: Deucravacitinib
Pregnant participants with psoriasis exposed to other systemic treatments for PsO
Drug: Other systemic treatments for PsO
Pregnant participants without psoriasis or any other autoimmune diseases
According to product label
According to product label
Number of major congenital malformations among infants
Time frame: 1-year post pregnancy outcome
Number of other pregnancy and infant outcomes
Other pregnancy and infant outcomes include: * Minor congenital malformations, * Small for gestational age * Small for age postnatal growth at 1 year of age * Serious or opportunistic infections * Neonatal hospitalization * Infant deaths * Neonatal deaths * Perinatal deaths * Spontaneous abortions * Stillbirths * Elective terminations/abortions * Preterm deliveries * Preeclampsia/eclampsia * Gestational hypertension
Time frame: 1-year post pregnancy outcome
Plan to share: No
Started Mar 2025 (actual). Primary completion is estimated for Apr 2028, 36 months after the start.
Of 81 industry-sponsored observational studies under Psoriasis, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 74. This study's planned 36 months is close to that.
Counting every sponsor, half of 174 studies reached it within 37 months; a quarter within 23 and three quarters within 93.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.